Trial Profile
A Phase II Single-Arm, Open-Label, Multi-Center Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2021
Price :
$35
*
At a glance
- Drugs Nitroxoline (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Proof of concept; Therapeutic Use
- Sponsors Jiangsu Yahong Meditech
- 27 Dec 2017 Status changed from active, no longer recruiting to completed according to an Asieris Pharmaceuticals media release.
- 27 Dec 2017 According to an Asieris Pharmaceuticals media release, results from this trial have been presented at the 2017 Bladder Cancer Research Symposium organized by the Albert Institute and MD Anderson Cancer Center, and at the 2017 Annual Meeting of Chinese Society of Clinical oncology (CSCO).
- 03 Mar 2016 New trial record